SARS-COV-2 Surrogate Virus Neutralisation Assay

Randox SARS-CoV-2 Surrogate Virus Neutralisation Assay qualitatively detects total neutralizing antibodies targeting the viral spike (S) protein receptor-binding domain (RBD) in an isotype- and species-independent manner.

Benefits include:

» Enables identification of a protective immune response to SARS-CoV-2.

» Aids in the stratification of at risk groups where additional booster vaccinations may be required.

» Accurate assessment of herd immunity and measurement of vaccine efficacy.

» Rapid results (1.5 hours) without the need for Biosafety level 3 requirements.

» Specificity of 100% and sensitivity of 98% compared to conventional virus neutralisation test.